SCHEMBL4638565

SCHEMBL4638565

O=C(c1nnn(Cc2cc(C(F)(F)F)cc(C(F)(F)F)c2)c1-c1ccccc1)c1c(-c2ccccc2Cl)nnn1CC1OCCO1

nearest known ligand 0.43

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.43
TSHR P16473 1/20 0.43
PTGER4 P35408 2/20 0.38
GAA P10253 1/20 0.38
CYP19A1 P11511 5/20 0.37
GRM2 Q14416 2/20 0.37
S1PR4 O95977 1/20 0.34
S1PR1 P21453 1/20 0.34
S1PR5 Q9H228 1/20 0.34
TACR1 P25103 1/20 0.34
IDO1 P14902 2/20 0.34
TDO2 P48775 2/20 0.34
AKR1C3 P42330 1/20 0.34
AKR1C2 P52895 1/20 0.34
ADORA3 P0DMS8 1/20 0.34
POLB P06746 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4637835 0.87 ALDH1A1 (0.43) ALDH1A1TSHRPTGER4GAACYP19A1
SCHEMBL6230808 0.86 ALDH1A1 (0.43) ALDH1A1TSHRPTGER4GAACYP19A1
SCHEMBL4639402 0.83 ALDH1A1 (0.40) ALDH1A1TSHRPTGER4GAACYP19A1
SCHEMBL4637902 0.81 ALDH1A1 (0.40) ALDH1A1TSHRGAACYP19A1GRM2
SCHEMBL4705766 0.81 ALDH1A1 (0.37) ALDH1A1TSHRPTGER4GAACYP19A1
SCHEMBL4638919 0.81 TACR1 (0.48) ALDH1A1TSHRGAACYP19A1GRM2
SCHEMBL4705903 0.79 IDH1 (0.44) ALDH1A1TSHRPTGER4GRM2
SCHEMBL4638603 0.79 ALDH1A1 (0.44) ALDH1A1TSHRGAACYP19A1GRM2
SCHEMBL4706457 0.79 ALDH1A1 (0.44) ALDH1A1TSHRGAACYP19A1GRM2
SCHEMBL4638479 0.79 ALDH1A1 (0.46) ALDH1A1TSHRGAACYP19A1GRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1501808-B1 TACHYKININ RECEPTOR ANTAGONISTS LILLY CO ELI (US) 2008-07-02 EP disclosed
US-7320994-B2 Triazole derivatives as tachykinin receptor antagonists ELI LILLY AND COMPANY (US) 2008-01-22 US disclosed
EP-1501809-B1 TRIAZOLE DERIVATIVES AS TACHYKININ RECEPTOR ANTAGONISTS LILLY CO ELI (US) 2008-01-16 EP disclosed
US-7179804-B2 Tachykinin receptor antagonists ELI LILLY AND COMPANY (US) 2007-02-20 US disclosed
US-20050239786-A1 Triazole derivatives as tachykinin receptor antagonists ELI LILLY COMPANY (US) 2005-10-27 US disclosed
US-20050239776-A1 Tachykinin receptor antagonists ELI LILLY AND COMPANY (US) 2005-10-27 US disclosed
EP-1501809-A1 TRIAZOLE DERIVATIVES AS TACHYKININ RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY (US) 2005-02-02 EP disclosed
EP-1501808-A1 TACHYKININ RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY (US) 2005-02-02 EP disclosed
WO-2003091227-A1 TACHYKININ RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY (US) 2003-11-06 WO disclosed
WO-2003091226-A1 TRIAZOLE DERIVATIVES AS TACHYKININ RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY (US) 2003-11-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050239786-A1 Triazole derivatives as tachykinin receptor antagonists TACR1, TACR2, BDKRB1 ALDH1A1 1408/4885TSHR 251/4885PTGER4 823/4885
US-20050239776-A1 Tachykinin receptor antagonists TACR2, TACR1, PROKR1 ALDH1A1 1988/4885TSHR 337/4885PTGER4 927/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.